RT Journal Article
SR Electronic
T1 Intolarence of pirfenidone and its associated factors in the real world
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP PA786
DO 10.1183/13993003.congress-2016.PA786
VO 48
IS suppl 60
A1 Teraoka, Shunsuke
A1 Fujimoto, Daichi
A1 Ito, Munehiro
A1 Nakagawa, Yoshihiro
A1 Ito, Jiro
A1 Kogo, Mariko
A1 Sato, Yuki
A1 Ryoji, Kato
A1 Nagata, Kazuma
A1 Nakagawa, Atsushi
A1 Otsuka, Kojiro
A1 Hatachi, Yukimasa
A1 Tomii, Keisuke
YR 2016
UL http://erj.ersjournals.com/content/48/suppl_60/PA786.abstract
AB [Background] Despite of evidences showing the benefit of pirfenidone, their use is frequently associated with some adverse effect which could result in discontinuation. We investigated the reason of intolerance and to identify predictors of tolerability to pirfenidone.[Methods] This retrospective study comprised 76 patients with pulmonary fibrosis who were treated with pirfenidone from January 2011 to January 2016. We evaluated the adverse effect affecting patient continuation of a stable maintenance dose.[Result] Nineteen of 76 failed to receive pirfenidone 1200mg/day. Anorexia was reported by eleven patients, which was largest population among the intolerance group. In the comparison to the tolerant group who succeeded in continuing more than 1200mg/day for a month, there was a significant association to prophylactic administration of dopamine receptor antagonists (38% vs 9%, p = 0.04).[Conclusion] This study reveal that anorexia is the most common reason for discontinuation of pirfenidone in the real world. Prophylactic administration of dopamine receptor antagonists provides a significant reduction of anorexia from pirfenione.